← Back to Patent Explorer
US4120951A Expired / Lapsed US ⏱️ 0.0 years remaining

Polypeptide hormones of the thymus

Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1977-05-09
•
Granted: 1978-10-17
•
Expires: 1997-05-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There are disclosed closely related new polypeptides isolated from bovine thymus, which are distinct polypeptides denoted as Thymin I and Thymin II or Thymopoietin I and Thymopoietin II, respectively. Thymin I may be characterized as having a relative mobility (Rf) on 7% polyacrylamide gel disc electrophoresis of 0.63 with respect to methyl green at a pH of 4.3, and having the following structural sequence:

Inventors

  • 👤 Gideon Goldstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 23:27
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/66; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/18

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 21 words
A therapeutic composition of matter comprising a therapeutically effective amount of the polypeptide: H 2 n--gly--gln--phe--leu--glu--asp--pro--ser--val--leu--thr--lys--glu--lys--leu--lys--ser--glu--leu--val--ala--asn--asn--val--thr--leu--pro--ala--gly--glu--gln--arg--lys--asp--val--tyr--val--gln--leu--tyr--leu--gln--his--leu--thr--ala--val--lys--arg--cooh, in a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim 21 words
A therapeutic composition of matter comprising a therapeutically effective amount of the polypeptide: H 2 n--gly--gln--phe--leu--glu--asp--pro--ser--val--leu--thr--lys--glu--lys--leu--lys--ser--glu--leu--val--ala--asn--asn--val--thr--leu--pro--ala--gly--glu--gln--arg--lys--asp--val--tyr--val--gln--leu--tyr--leu--gln--his--leu--thr--ala--val--lys--arg--cooh, in a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim 23 words
A therapeutic composition according to claim 1 wherein the therapeutically effective amount of polypeptide is at least about 0.20 μg/kg of body weight.
Claim 4
Dependent Claim 21 words
A therapeutic composition of matter comprising a therapeutically effective amount of the polypeptide: H 2 n--ser--gln--phe--leu--glu--asp--pro--ser--val--leu--thr--lys--glu--lys--leu--lys--ser--glu--leu--val--ala--asn--asn--val--thr--leu--pro--ala--gly--glu--gln--arg--lys--asp--val--tyr--val--gln--leu--tyr--leu--gln--thr--leu--thr--ala--val--lys--arg--cooh, in a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim 21 words
A therapeutic composition of matter comprising a therapeutically effective amount of the polypeptide: H 2 n--ser--gln--phe--leu--glu--asp--pro--ser--val--leu--thr--lys--glu--lys--leu--lys--ser--glu--leu--val--ala--asn--asn--val--thr--leu--pro--ala--gly--glu--gln--arg--lys--asp--val--tyr--val--gln--leu--tyr--leu--gln--thr--leu--thr--ala--val--lys--arg--cooh, in a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim 23 words
A therapeutic composition according to claim 3 wherein the therapuetically effective amount of polypeptide is at least about 1.3 μg/kg of body weight.
Claim 7
Dependent Claim 29 words
A method for the treatment of conditions resulting from relative or absolute T cell deficiencies which comprises administration of a pharmaceutically effective amount of the composition of claim 1.
Claim 8
Dependent Claim 29 words
A method for the treatment of conditions resulting from relative or absolute T cell deficiencies which comprises administration of a pharmaceutically effective amount of the composition of claim 3.
Claim 9
Dependent Claim 28 words
A method for inducing bone marrow cells to develop the characteristics of thymus-derived lymphocytes which comprises administration of a therapeutically effective amount of the composition of claim 1.
Claim 10
Dependent Claim 28 words
A method for inducing bone marrow cells to develop the characteristics of thymus-derived lymphocytes which comprises administration of a therapeutically effective amount of the composition of claim 3.
Claim 11
Dependent Claim 37 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficiencies of the thymus which comprises administration of a therapeutically effective amount of the composition of claim 1.
Claim 12
Dependent Claim 37 words
A method for affecting the immune response in the body to assist in the correction of relative or absolute deficiencies of the thymus which comprises administration of a therapeutically effective amount of the composition of claim 3.
Claim 13
Dependent Claim 26 words
A method for the treatment of conditions resulting from excess neuromuscular activity which comprises administration of a therapeutically effective amount of the composition of claim 1.
Claim 14
Dependent Claim 26 words
A method for the treatment of conditions resulting from excess neuromuscular activity which comprises administration of a therapeutically effective amount of the composition of claim 3.
Claim 15
Dependent Claim 25 words
A method for inhibiting the uncontrolled proliferation of thymin-responsive lymphocytes which comprises a administration of a therapeutically effective amount of the composition of claim 1.
Claim 16
Dependent Claim 24 words
A method for inhibiting the uncontrolled proliferation of thymin-responsive lymphocytes which comprises administration of a therapeutically effective amount of the composition of claim 3.
Claim 17
Dependent Claim 26 words
A method for enhancing the cellular immune responses mediated by T cells which comprises administration of a therapeutically effective amount of the composition of claim 1.
Claim 18
Dependent Claim 26 words
A method for enhancing the cellular immune responses mediated by T cells which comprises administration of a therapeutically effective amount of the composition of claim 3.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-10-16 1982-04-17 1982-10-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-10-16 1986-04-17 1986-10-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-10-16 1990-04-17 1990-10-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag